Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion

Drug developer Atavistik Bio said on Thursday it has signed a deal with Swiss drugmaker Roche BX:RHO potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases.Here are some details